This isn't a rare disease we're talking about, and we're talking about finding only 14 people. What are they going to do in a Ph 3 trial when they need to find hundreds of participants? I don't want to count on the standards being relaxed. I see a big problem with execution, and at this share price, so does the market.
News 
Market Data 
Discover 
